Ganoderic acids suppress growth and angiogenesis by modulating the NF-κB signaling pathway in breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Ganoderma acids show potential in suppressing breast cancer growth, angiogenesis, and invasiveness.
• The precise mechanism of action for ganoderma acids in breast cancer remains largely unexplored.
• Understanding these mechanisms is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To investigate the effects of ganoderic acid Me (GA-Me) on cellular phenotypes and tumor growth in MDA-MB-231 breast cancer cells.
• To elucidate the underlying molecular mechanisms, particularly the role of the nuclear factor kappaB (NF-κB) signaling pathway.

Main Methods:

• Treatment of MDA-MB-231 cells with GA-Me, assessing effects on NF-κB activity, proliferation, invasion, and apoptosis.
• Analysis of NF-κB-regulated gene expression, including genes involved in proliferation, anti-apoptosis, invasion, and angiogenesis.
• In vivo studies involving intraperitoneal administration of GA-Me to evaluate tumor growth inhibition in a xenograft model.

Main Results:

• GA-Me significantly inhibited NF-κB activity in MDA-MB-231 cells, even when stimulated with tumor necrosis factor-alpha (TNF-α).
• GA-Me suppressed proliferation and invasion, and induced apoptosis, mediated through the inhibition of NF-κB signaling.
• GA-Me down-regulated key NF-κB target genes (c-Myc, cyclin D1, Bcl-2, MMP-9, VEGF, IL-6, IL-8) and inhibited tumor growth in vivo.

Conclusions:

• GA-Me effectively inhibits breast cancer cell proliferation, invasion, and angiogenesis while promoting apoptosis by suppressing NF-κB activity.
• GA-Me modulates the expression of critical downstream genes within the NF-κB signaling pathway.
• These findings highlight GA-Me as a potential therapeutic agent for breast cancer, targeting the NF-κB pathway.